Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco

On December 31, 2018 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, reported that Mr. Eyal Barad, CEO, will be in San Francisco in January 2019 during the J.P. Morgan Healthcare Conference (Press release, Cannabics Pharmaceuticals, DEC 31, 2018, View Source [SID1234532315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will be meeting with Investors as well as potential partners such as Pharmaceuticals and Biotech firms from Monday, January 7th to Wednesday, January 9th.

Mr. Barad will provide an overview on the company’s mission and provide insight into the path forward towards bringing a highly valuable and needed solution to cancer patients.

Cannabics Pharmaceuticals proprietary IP, alongside its drug discovery platform and AI predictive capabilities, is based on a personalized approach to treat cancer and its side effects. The company’s goals are to leverage its technology and look at new partnerships when meeting with some of these Life Sciences companies.